Literature DB >> 3086177

Cytoprotection by a synthetic prostaglandin against ethanol-induced gastric mucosal damage. A double-blind endoscopic study in human subjects.

N M Agrawal, T Godiwala, A Arimura, E Z Dajani.   

Abstract

This randomized, double-blind, placebo-controlled study compared the cytoprotective effects of misoprostol, a synthetic analog of prostaglandin E1, and cimetidine on ethanol-induced gastric mucosal damage. Forty-five healthy male subjects were accepted, following endoscopy to exclude those with upper gastrointestinal disease. Injury to the gastric mucosa was induced by spraying it with 80% ethanol solution. Misoprostol (200 micrograms) intragastrically or cimetidine (300 mg) orally or placebo was administrated before the ethanol challenge. The gastric mucosa was graded using a seven-point endoscopic scale by two endoscopists 15 and 30 min after ethanol instillation. Thirty minutes following the instillation of ethanol, the gastric mucosa of placebo-treated subjects showed marked damage, with an endoscopic score (mean +/- standard deviation) of 5.5 +/- 0.9. Cimetidine partially prevented gastric mucosal damage, with an endoscopic score of 4.5 +/- 1.7 as compared to placebo (p = 0.04). Misoprostol significantly prevented gastric mucosal injury with a mean endoscopic score of 1 +/- 1.7 when compared to placebo (p = 0.0001) and to cimetidine (p = 0.0002). This cytoprotective action of misoprostol may prove to be clinically very important and warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086177     DOI: 10.1016/s0016-5107(86)71757-4

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  11 in total

1.  Effect of rioprostil, a methylprostaglandin E1 analog, on basal and stimulated plasma pancreatic hormone levels in man.

Authors:  O Segers; G Somers
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

Review 2.  Misoprostol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.

Authors:  J P Monk; S P Clissold
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

3.  Prostaglandins in peptic ulcer disease. An overview of current status and future directions.

Authors:  S J Sontag
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

4.  Involvement of alpha 2-adrenoceptors in mechanism of intragastric nicotine protection against ethanol injury in rat stomach.

Authors:  K Endoh; J Kao; M Baker; F W Leung
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

5.  Mechanism of intragastric tetramethylammonium protection against 40% ethanol injury in rat stomach.

Authors:  K Endoh; J Kao; M Baker; O U Scremin; F W Leung
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

6.  Involvement of alpha(2)-adrenoceptors in the gastric protective effect of nitroglycerin against acidified ethanol-induced mucosal injury.

Authors:  Felix W Leung; Chi Chung Chan
Journal:  Dig Dis Sci       Date:  2007-03-30       Impact factor: 3.199

7.  Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study.

Authors:  N M Agrawal; H E Van Kerckhove; L J Erhardt; G S Geis
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

8.  Misoprostol reduces indomethacin-induced changes in human small intestinal permeability.

Authors:  I Bjarnason; P Smethurst; C G Fenn; C E Lee; I S Menzies; A J Levi
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

9.  Intragastric nicotine protection against 40% ethanol injury in rat stomach. Role of ganglionic stimulation or blockade.

Authors:  K Endoh; J Kao; M Baker; F W Leung
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

10.  Dose-response, meal-stimulated gastric antisecretory study of prostaglandin E1 analog, misoprostol, in man.

Authors:  G R Davis; J S Fordtran; E Z Dajani
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.